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C
DObjective: A negative relationship between coronary stenting before coronary artery bypass graft (CABG) sur-
gery and the perioperative mortality and morbidity has been shown in diabetic patients. We tried to assess this
relationship in a 2-institution database.
Methods: In the years 2005 and 2006, 1125 of 3311 patients undergoing CABG surgery had diabetes mellitus
(33.9%), and 185 (16.4%) of the diabetic patients had at least 1 previous stent. There was no evidence of any
clinically significant difference in the preoperative and intraoperative parameters between diabetics with or
without previous stents.
Results: Thirty-day mortality (no-stent group, 3.86%; stent group, 1.62%) and postoperativemajor adverse car-
diovascular and cerebrovascular events (MACCEs; mortality, stroke, myocardial infarction, renal failure) (no-
stent group, 12.2%; stent group, 5.9%) occurred more often in diabetic patients without coronary stents. Logis-
tic regression for 30-day mortality using possible confounders including preoperative stent showed a significant
positive effect of preoperative coronary stenting (OR, 0.157; 95% CI limits, 0.033-0.737). Taking percutaneous
coronary intervention out of the calculation model, this positive effect was no longer significant (OR, 0.344; CI,
0.091-1.298). Logistic regression for perioperative MACCE, with as well as without percutaneous coronary
intervention as a confounder, also showed a significant positive effect of preoperative coronary stenting
(OR, 0.231; 95% CI, 0.091-0.590).
Conclusions: Coronary stenting before CAGB in diabetic patients does not predispose to a higher perioperative
risk regarding mortality and morbidity after CABG surgery. (J Thorac Cardiovasc Surg 2011;142:e53-7)A negative relationship between coronary stenting before
coronary artery bypass grafting (CABG) surgery and the
perioperative mortality and morbidity has been shown by
Thielmann and associates for multiple coronary stenting
in diabetic patients,1 as well as in patients without diabetes.2
This could be reproduced by other authors.3,4 Although
these manuscripts showed a worse outcome after cardiac
surgery in patients who were underwent stenting before
CABG compared with those not receiving stents, the
causal relationship remained unclear. Authors showing
a higher perioperative mortality in patients with
a previous stent before CABG could only speculate about
reasons for the worse surgical outcome in previously
stented patients:
 Coronary endothelial injury with intimal hyperplasia ow-
ing to repeat stent lesions5,6e Departments of Cardiovascular Surgerya andMedical Statistics,b University
essen; and the Department of Cardiovascular Surgery,c Kerckhoff Clinic, Bad
eim, Germany.
ures: Authors have nothing to disclose with regard to commercial support.
d for publication July 30, 2010; revisions received Nov 9, 2010; accepted for
cation April 15, 2011.
for reprints: Andreas Boening, MD, PhD, Department of Cardiovascular Sur-
University Hospital Giessen, Rudolf-Buchheim-Straasse 7, 35392 Giessen,
any (E-mail: andreas.boening@chiru.med.uni-giessen.de).
23/$36.00
ht  2011 by The American Association for Thoracic Surgery
016/j.jtcvs.2011.04.018
The Journal of Thoracic and Ca Microvascular thrombotic obstruction and/or distal mi-
croembolization owing to platelet microaggregates7,8
 Compromised collateral blood flow by multiple contigu-
ous and overlapping stents9
 Surgical coronary anastomoses have to be done on pe-
ripheral vessel regions where the target vessels are
smaller in diameter, possibly leading to a compromised
runoff and/or impaired patency rate2
 Preexisting stent-induced myocardial damage, side
branch occlusion after stent3
 Perioperative stent thrombosis3
 Multiple small infarctions during/after percutaneous cor-
onary intervention (PCI) shown by troponin I release10
leading to left ventricular mass loss by irreversible myo-
cardial injury11
Using a 2-institutional database, we tried to assess the
negative relationship between preoperative coronary stent-
ing and postoperative results after CABG surgery. The pa-
rameters of choice were (1) 30-day survival and (2) the
rate of perioperative major adverse cardiovascular and cere-
brovascular events (MACCEs) (mortality, cerebrovascular
infarctions, myocardial infarctions, and renal failure).
METHODS
Study Population
In an attempt to reproduce the negative influence of stenting before
CABG, we analyzed retrospectively the surgical database of 2 institutions.rdiovascular Surgery c Volume 142, Number 2 e53
Abbreviations and Acronyms
CABG ¼ coronary artery bypass grafting
CI ¼ confidence interval
ECC ¼ extracorporeal circulation
IABP ¼ intra-aortic balloon pump
MACCE ¼ major adverse cardiovascular and
cerebrovascular event
OR ¼ odds ratio
PCI ¼ percutaneous coronary intervention
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DWe used the German Health Quality System (BQS Institute for Quality and
Patient Safety) as a base for our data evaluation and added several items of
interest, gaining 209 items in total. Altogether, therewas information about
3311 patients undergoing isolated CABG in the years 2005 and 2006 in our
2 institutions.
Of the 3311 patients, 1125 (34.0%) had diabetes mellitus. The diabetic
patients were not classified according to the kind of diabetes or according to
the duration of their diabetic state, but only according to their actual treat-
ment: no treatment (0% of the stent group, 0.5% of the no-stent group),
diet only (10.8% of the stent group, 13.7% of the no-stent group), oral
medication (47.6% of the stent group, 44.7% of the no-stent group), insu-
lin therapy (41.6% of the stent group, 41.1% of the no-stent group).
Owing to missing data concerning the dependent and independent vari-
ables of interest, only 1092 of the 1125 patients went into the final analysis,
and 185 (16.9%) of these 1092 diabetic patients were stented. The median
time between last stenting and surgery was 82.5 days (n¼ 42, range 0-3186
days). The majority of stents (113; 71.5%) were bare-metal stents, whereas
only 16 (16.5%) were drug-eluting stents. Nineteen (12.0%) patients had
a combination of both.
The numbers of interventions with stent implantation were as follows:
only 1 PCI (72.6% of the stent group), 2 PCIs (20.6% of the stent group),
3 PCIs (5.5% of the stent group), and more than 4 PCIs (1.4% of the stent
group).
Indications for CABG surgery were de novo stenoses in 40.9% (n¼ 72)
and in-stent restenoses—either alone or combined with de novo stenoses—
in 59.1% (n ¼ 104). Because of the high patient numbers, even small, and
possibly clinically irrelevant, differences reach statistical significance.
Definitions
Thirty-day mortality included all deaths within this time frame. MAC-
CEswere new-onset myocardial infarction, dialysis, stroke, or 30-day mor-
tality. Stroke was a persistent or transitory neurologic event. Myocardial
infarction was defined as maximum creatine kinase MB elevation 3 times
above the upper normal level and new Q waves in the electrocardiogram or
the proof of new wall motion disturbances in the echocardiogram. Com-
plete revascularization was defined as all planned anastomoses done.
Perioperative Management
Myocardial revascularization was performed in all patients via median
sternotomy and a heparin dose suited to keep activated coagulation time
greater than 400 seconds. Protamine was administered to antagonize hep-
arin in a 1:1 dose. All patients received aspirin after surgery (beginning
orally on day 1); clopidogrel was given only in patients with stents having
an indication for this drug.
In both groups, the majority of the patients (n ¼ 988, 97.9% no-stent
group; n¼ 181, 97.8% previous stent group) were operated on using extra-
corporeal circulation (ECC) with mild hypothermia (32C-34C), ascend-
ing aortic and venous 2-stage cannulation, as well as Bretschneider
cardioplegia (n ¼ 196; 21.6% no-stent group, n ¼ 41; 22.2% previous-e54 The Journal of Thoracic and Cardiovascular Surgstent group), or blood cardioplegia (n ¼ 678; 74.8% no-stent group,
n ¼ 138; 74.6 previous-stent group). There was a high percentage of inter-
nal thoracic artery use (n ¼ 873; 96.4% no-stent group, n ¼ 164; 88.7%
previous-stent group). Bilateral internal thoracic artery use (n ¼ 121;
13.4% no-stent group, n ¼ 22; 11.9% previous-stent group) and radial ar-
tery use (n ¼ 170; 18.8% no-stent group, n ¼ 41; 22.2% previous-stent
group) was more frequent than reported for German heart centers.12
The number of grafts was as follows: 1 bypass graft (3.2% of the stent
group, 1.7% of the no-stent group), 2 bypass grafts (32.4% of the stent
group, 22.7% of the no-stent group), 3 bypass grafts (52.9% of the
stent group, 61.4% of the no-stent group), 4 bypass grafts (10.3% of the
stent group, 12.4% of the no-stent group), 5 bypass grafts (0.5% of
the stent group, 1.5% of the no-stent group), and 6 bypass grafts (0.5%
of the stent group, 0.1% of the no-stent group).
Statistical Analysis
A descriptive statistical analysis comparing diabetic patients in the
stented and nonstented groups was carried out using the SAS statistical sys-
tem version 9.2 (SAS Institute, Inc, Cary, NC). Fisher’s exact test was used
to test differences between patients with or without a stent in case of nom-
inal or ordinal scaled variables. The Hodges-Lehmann estimator was cal-
culated to determine differences between population medians. Inasmuch
as the continuous variables of interest were not normally distributed, the
Wilcoxon-Mann-Whitney test was used to test possible differences be-
tween the location of the distribution in both groups. To prove homogeneity
concerning the possible confounders, we computed the Mann-Whitney es-
timator (associated effect size measure for the Wilcoxon-Mann-Whitney
test) and the corresponding 90% confidence interval (CI).
In a first step, the influence of the possible confounders (preoperative
data: intra-aortic balloon pumping [IABP], preoperative PCI, EuroSCORE;
intraoperative data: complete revascularization, ECC time) on 30-day mor-
tality or MACCE, respectively, was evaluated. Because preoperative fac-
tors like age, gender, and left ventricular function were included in the
EuroSCORE, these factors were not analyzed separately. In a second
step, the associations between the possible confounders were evaluated.
Taking these results into account from the clinical point of view, a model
for logistic regression to investigate the influence of preoperative stenting
on 30-day mortality or occurrence of MACCE, respectively, was defined.
Both analyses included IABP, PCI, and EuroSCORE before surgery, in-
traoperative ECC time, and complete revascularization as confounders.
These analyses were done in an exploratory sense; therefore, all computed
P values will be given.RESULTS
Testing homogeneity, small-sized group differences in
the preoperative and intraoperative parameters between pa-
tients with coronary stents (stent group) and patients without
coronary stents (no-stent group) could be observed for only
3 parameters using the Mann-Whitney estimator for group
differences: patients in the stent group were younger (68
vs 70 years) and had more reoperations (13.0 vs 3.3%), as
well as fewer neurologic diseases (3.8 vs 8.8%) (Table 1).
Although procedure time was similar in both groups dur-
ing surgery, ECC time and aortic clamping timewere longer
in the no-stent group (Table 2).
The rates of 30-daymortality (no-stent group, 3.86%; stent
group, 1.62%; P Fisher’s exact ¼ .184) and MACCEs (no-stent
group, 10.0%, stent group, 4.3%, P Fisher’s exact¼ .012) were
higher in the no-stent group (Table 3). In accordance with
these univariate results, the multivariate analyses couldery c August 2011
TABLE 1. Demographic data of diabetic patients before surgery
Value
CABG without stent
(n ¼ 907); median (range)
Stent before CABG
(n ¼ 185); median (range) P value
Mann-Whitney estimate
P (X<Y) 90% CI
Age (y) 70 (34–88) 68 (37–85) .018* .445 0.407–0.482
Gender (M/F) 72.2%/27.8% 71.4%/28.6% .857* .504 0.466–0.543
Height (cm) 170 (146–197) 170 (150–195) .838y .478 0.441–0.516
Weight (kg) 83 (41–138) 83 (50–119) .929y .501 0.463–0.538
BMI .711* .506 0.468–0.543
15–20 1.0% 0.0%
20–25 18.5% 17.8%
25–30 44.1% 45.9%
30–35 36.4% 36.2%
LVEDP 15 (0–48) 15 (0–50) .476y .506 0.458–0.554
LVEF (% of patients) 0.739* 0.516 0.478–0.554
<30% 6.2 5.4
30%50% 28.3 25.9
>50% 65.5 68.7
Three-vessel disease 86.6% 87.6% .255* .506 0.468–0.544
EuroSCORE 5 (0–17) 5 (0-21) .982y .498 0.460–0.537
Previous cardiac surgery (%) 3.3% 13.0% <.001* .548 0.508–0.588
Emergency 3.5% 5.4% .434* .493 0.455–0.532
Atrial fibrillation 8.1% 5.4% .449* .489 0.451–0.527
Cardiogenic shock 1.1% 1.1% 1.000* .500 0.462–0.538
Left main stenosis 25.4% 26.4% .780* .505 0.466–0.544
Dialysis 2.3% 2.2% .496* .491 0.453–0.529
Peripheral vascular disease 28.5% 26.5% .654* .490 0.452–0.528
Neurologic diseases 8.8% 3.8% .024* .475 0.438–0.512
CABG, Coronary artery bypass graft; CI, confidence interval; M/F, male/female; BMI, body mass index; LVEFP, left ventricular end-diastolic pressure; LVEF, left ventricular
ejection fraction. *Fisher’s exact test. yMedian test.
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Dshow a connection between preoperative stenting and the re-
sults of CABG (Tables 4 and 5) when the parameters
EuroSCORE, intraoperative IABP insertion, complete
revascularization, ECC time, und preoperative PCI were
included in the analysis as possible confounders. Especially
for the dependent variable 30-day mortality, the possible
influence of the independent variable stenting depends on
the set of confounders in the model. With the 5
confounders mentioned above, patients with stenting before
surgery had a significantly (P ¼.019; odds ratio [OR],
0.157; 95% CI, 0.03-0.74) lower mortality risk. Leaving
out the confounder PCI, the mortality risk was not
significantly different anymore (P ¼ .115; OR, 0.344; 95%
CI, 0.09-1.29). That means that, depending on the
calculation model, in our patient group the risk of dying
early after CABG surgery for diabetic patients with stenting
before surgery was either lower than or equal to, but notTABLE 2. Intraoperative data
Value
CABG without stent
(n ¼ 907); median (range)
Stent be
(n ¼ 185);
Procedure time (min) 215 (99–476) 215 (
ECC time (min) 103 (0–260) 100 (
Aortic clamping time (min) 63 (0–195) 60 (
Complete revascularization 89.1% 8
CABG, Coronary artery bypass graft; CI, confidence interval; ECC, extracorporeal circula
The Journal of Thoracic and Cahigher than, that for nonstented diabetic patients. We could
not find evidence supporting former reports of a higher
perioperative death risk for patients with coronary stenting
before CABG surgery.
For the perioperative MACCE rate, the same applies, but
the influence of stenting on the MACCE rate is less depen-
dent on the set of confounders in the model.
We found a significantly higher cerebrovascular event
rate in the no-stent group (no-stent group, 4.41%; stent
group, 1.08%; P Fisher’s exact ¼ .034). Postoperative median
length of stay in the hospital (8 days in both groups) was not
significantly different between the groups.
DISCUSSION
This retrospective study (n ¼ 1092) cannot confirm pre-
viously published reports stating that multiple previous
stenting is associated with a high mortality after CABGfore CABG
median (range) P
Mann-Whitney estimate
P (X<Y) 90% CI
110–606) .977* .487 0.450–0.523
0–230) .077* .455 0.417–.0492
0–157) .054* .458 0.421–0.495
9.7% .897y .503 0.465–0.541
tion. *Median test. yFisher’s exact test.
rdiovascular Surgery c Volume 142, Number 2 e55
TABLE 3. Postoperative data
Value
CABG
without stent
(n ¼ 907);%
Stent before
CABG
(n ¼ 185);%
P (Fisher’s
exact test)
Thirty-day mortality 3.86 1.62 .184
MACCE 10.0 4.3 .012
Myocardial infarction 1.10 0.54 .701
Rethoracotomy 5.40 4.32 .716
Cerebrovascular event 4.41 1.08 .034
Dialysis 2.87 2.70 1.000
Blood transfusion 41.28 46.49 .192
Infection 10.69 6.49 .105
Atrial fibrillation 29.3 27.6 .658
CABG, Coronary artery bypass graft;MACCE, major adverse cardiovascular and ce-
rebrovascular event.
TABLE 5. Logistic regression for the response variable MACCE in
1092 diabetic CABG patients (with and without confounder PCI)
Variable P value OR 95% CI
Stenting before surgery (confounders:
PCI, EuroSCORE, IABP, complete
revascularization, ECC time)
.002 0.232 0.091–0.593
Stenting before surgery (confounders:
EuroSCORE, IABP, complete
revascularization, ECC time)
.0151 0.383 0.176–0.830
MACCE, Major adverse cardiovascular and cerebrovascular event; CABG, coronary
artery bypass graft; PCI, percutaneous coronary intervention;OR, odds ratio;CI, con-
fidence interval; IABP, intra-aortic balloon pump; ECC, extracorporeal circulation.
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Dsurgery.1-4 This association has also been described for
diabetic patients, in whom not multiple, but single
stenting has been shown as a risk factor.1 In our data set,
we found no evidence that single or multiple stenting before
surgery increases the surgical risk in patients with coronary
artery disease who have diabetes. In the previously pub-
lished reports1-4 with meticulously used and elaborate
statistical methods, no evidence was given about the
causality and the pathomechanisms of a higher surgical
mortality in previously stented patients.
Checking the homogeneity of the 2 groups regarding de-
mographic data before surgery, we found that small inter-
group differences could be observed in only 3 of the 17
variables (age, previous cardiac surgery, and neurologic dis-
eases) using the Mann-Whitney estimator for group differ-
ences (Table 1). Similarly, small differences between the 2
groups were seen regarding the intraoperative data: ECC
time and aortic clamping time (Table 2). Why should a dif-
ference of 3 minutes (Hodges-Lehmann estimator for aortic
clamping time, Table 2) or of 5 minutes (Hodges-Lehmann
estimator for ECC time medians) cause a remarkable clini-
cal difference between the 2 investigated groups?
The main end points of our study, 30-day mortality and
MACCE rate, are different between patients having a stent
before surgery or not. However, in contrast to the mentionedTABLE 4. Logistic regression for the response variable survival in
1092 diabetic CABG patients (with and without confounder stent)
Variable P value OR CI
Stenting before surgery
(with confounders: PCI, EuroSCORE,
IABP, complete revascularization,
ECC time)
.019 0.157 0.033–0.738
Stenting before surgery (with
confounders: EuroSCORE, IABP,
complete revascularization,
ECC time)
.115 0.344 0.091–1.298
CABG, Coronary artery bypass graft; OR, odds ratio; CI, confidence interval; PCI,
percutaneous coronary intervention; IABP, intra-aortic balloon pump; ECC, extracor-
poreal circulation.
e56 The Journal of Thoracic and Cardiovascular Surgprevious studies, these differences were in favor of stenting
before surgery! Depending on inclusion of the confounder
PCI into the analysis, in the multivariate (Table 5) logistic
regression, stenting before surgery was an influencing fac-
tor for our 2 study end points or not. Why patients with
stents before surgery should have a better outcome after sur-
gery is unclear; therefore, we are cautious about overinter-
preting our data in that direction, especially in the light of
our second finding that the differences between no-stent
and stent patients vanish if we take the confounder PCI
out of the calculation. One reason that stented patients
fare better over the CABG surgery phase could be that
they are usually treated with platelet inhibitors either dually
or for a longer period of time without stopping this treat-
ment before surgery.
We are well aware that our results are in direct contrast to
previously published results of several authors: The most
recent analysis of Massoudy and associates4 and the article
by Thielmann and colleagues,2 show that patients with
more than 2 coronary interventions before coronary surgery
have a higher surgical risk than patients without or with
only 1 coronary stent. However, these authors fail to de-
scribe convincingly the reasons for this higher surgical risk.
Differences to other publications are that we did not limit
our analysis to elective patients2 but included every consec-
utive patient having isolated CABG surgery in this 2-year
period into this analysis. We did avoid a case–control anal-
ysis over a long time period3 but chose a complete data set
analysis of all consecutive patients having CABG surgery
within a narrow 2-year time frame. Whereas Massoudy
and associates4 described MACCEs and mortality only as
in-hospital data, we produced 30-day data.
In contrast to the article of Bonaros and colleagues,3 pa-
tients of the stent group in our study did not experience
more perioperative complications (new renal insufficiency,
rethoracotomies, blood transfusions) than did patients in the
no-stent group. This difference is explainable by a worse
preoperative status regarding history of myocardial infarc-
tions, left ventricular ejection fraction, and the use of plate-
let antiaggregation agents of the stent patients in Bonaros’
study3 but not in our study.ery c August 2011
Boening et al Acquired Cardiovascular DiseaseLong-term results are analyzed by Chocron and col-
leagues,13 who described a higher incidence of MACCEs
in patients with previous stenting (17.0%) than in patients
without previous stenting (11.6%) before CABG surgery.
The time frame of this study based on the dataset of the
IMAGINE trial was a follow-up time of 2.95 years. Nothing
is mentioned regarding the short-term results of CABG after
coronary stenting in this report.A
C
DLimitations
With our analysis, we can only state that in our patient
cohort there is a possible relationship between coronary
stenting and the results of subsequent coronary surgery,
but in a completely different way from those described in
previous articles. The causality of this relationship is un-
clear so far.
Although a causal relationship between previous coro-
nary stent and worse results after CABG surgery has not
been proven, and our results speak against this hypothesis,
more trials—prospective and/or randomized—have to be
done. This causal relationship could possibly be explained
from a prospective randomized trial,14 where the mortality
of first interventionally but then surgically treated coronary
patients could be compared with the results of first surgi-
cally treated patients.
Although in our group of patients we could not show that
coronary stenting before CAGB predisposes to a higher
perioperative risk regarding mortality and morbidity after
CABG surgery, caution is warranted: the current practice
of stenting a coronary artery first and sending the patient
to surgery if stenting fails has to be questioned.CONCLUSIONS
In our group of diabetic patients, coronary stenting before
CAGB does not increase the perioperative risk regarding
mortality and morbidity of CABG surgery. In the light of
contradictory results of other studies, the current practiceThe Journal of Thoracic and Caof stenting a coronary artery first and sending the patient
to surgery if stenting fails has to be questioned.
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